Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PIMECROLIMUS vs ELIDEL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pimecrolimus is a calcineurin inhibitor that binds to macrophilin-12 (FKBP-12) and inhibits calcineurin-dependent T-cell activation, thereby suppressing pro-inflammatory cytokine production (e.g., IL-2, IFN-γ) and mast cell degranulation.
Inhibits T-cell activation by binding to macrophilin-12 (FKBP-12) and inhibiting calcineurin, thereby blocking cytokine transcription.
Mild to moderate atopic dermatitis in immunocompetent patients aged 2 years and older,Off-label: psoriasis, seborrheic dermatitis, vitiligo, lupus erythematosus
Atopic dermatitis unresponsive to or intolerant of other topical treatments,Off-label: psoriasis, vitiligo, rosacea, contact dermatitis, lichen sclerosus, cutaneous lupus erythematosus
Topical: Apply a thin layer of 1% cream to affected areas twice daily. Maximum daily dose: not established; usual amount is pea-sized per application. Not for continuous long-term use; intermittent use only.
Apply a thin layer of 1% cream to affected areas twice daily.
Terminal elimination half-life is approximately 65 hours (range 22–115 hours) in adult atopic dermatitis patients, reflecting slow systemic clearance.
Terminal elimination half-life: 30–45 hours (mean 35 hours) following topical application; clinically, twice-daily dosing ensures therapeutic concentrations.
Primarily metabolized via hepatic cytochrome P450 3A4 (CYP3A4) to O-demethylated metabolites; also undergoes further hydroxylation and glucuronidation.
Metabolized primarily by CYP3A4; major metabolite O-demethylated pimecrolimus.
Primarily fecal (78.4% of dose) via biliary excretion; renal elimination accounts for <1% of unchanged drug.
Renal (negligible, <1% unchanged) and biliary/fecal (approximately 97% as metabolites); less than 1% of the dose is excreted renally as unchanged drug.
99.5% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
99% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein).
Approximately 1.3 L/kg (range 0.6–2.1 L/kg), indicating extensive tissue distribution.
Vd ~ 10 L/kg (extensive tissue distribution); suggests significant extravascular binding and penetration into tissues.
Topical: Systemic bioavailability is very low (<0.5% of applied dose) based on blood concentration measurements.
Topical: Systemic bioavailability is approximately 4% (range 1–7%) of applied dose; absorption increases with extent of skin lesion and thickness of application.
No dose adjustment required for renal impairment; systemic absorption is minimal (<2.5%).
No dose adjustment required for any degree of renal impairment.
No formal studies in hepatic impairment; based on minimal systemic absorption, no adjustment is likely required, but use caution in severe hepatic impairment due to theoretical risk of increased exposure.
No formal studies in hepatic impairment; use caution in severe impairment.
Children ≥2 years: Apply a thin layer of 1% cream to affected areas twice daily; maximum application area: <20% body surface area. Avoid use in children <2 years due to risk of systemic effects (insufficient data).
Apply a thin layer of 1% cream twice daily for children aged 2 years and older; not indicated for children under 2 years.
No specific dose adjustment; use lowest effective amount due to potential for increased skin sensitivity and renal function decline with age.
No specific dose adjustment recommended; apply a thin layer of 1% cream twice daily as for adults.
Long-term safety of topical calcineurin inhibitors has not been established; rare cases of malignancy (e.g., lymphoma, skin cancer) have been reported; avoid continuous long-term use; limit use to indicated short-term and intermittent treatment.
Long-term safety of topical calcineurin inhibitors has not been established; rare cases of malignancy (e.g., lymphoma, skin cancer) have been reported; use should be limited to short-term and intermittent treatment.
Increased risk of infections (e.g., varicella zoster, herpes simplex); avoid use on active infections; possible lymphadenopathy; photosensitivity (avoid UV exposure); monitor for skin atrophy; not recommended in children <2 years; use during pregnancy only if clearly needed.
Increased risk of infections (e.g., eczema herpeticum, varicella zoster); avoid use on malignant or premalignant skin conditions; lymphadenopathy; photosensitivity; not recommended in patients with Netherton syndrome; potential for systemic immunosuppression; monitor for local irritation.
History of hypersensitivity to pimecrolimus or any component of the formulation; Netherton syndrome; generalized erythroderma; active viral, bacterial, or fungal skin infections at application site.
Hypersensitivity to pimecrolimus or any component of the formulation; history of malignancy; application to areas of active infection; Netherton syndrome; immunocompromised patients.
No known food interactions with topical pimecrolimus. Oral ingestion should be avoided; however, accidental small amounts on skin are unlikely to cause systemic effects.
No known food interactions. Avoid grapefruit juice as it may increase drug levels (CYP3A4 inhibition).
Pimecrolimus is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and fetotoxicity at doses 35 times the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. First trimester: theoretical risk due to systemic absorption; avoid if possible. Second and third trimesters: limited data; risk of fetal harm cannot be excluded.
FDA Pregnancy Category C. Systemic exposure is minimal after topical application, but animal studies have shown developmental toxicity. No adequate human studies; risk cannot be excluded. Avoid in pregnancy unless clearly needed.
It is not known whether pimecrolimus is excreted in human milk. Systemic absorption after topical application is minimal (<2.5 ng/m L), suggesting negligible transfer. However, due to potential for serious adverse reactions in nursing infants, caution should be exercised. M/P ratio is not available. Breastfeeding is generally considered acceptable with cautious use.
Not recommended. Pimecrolimus is excreted in milk in animal studies; unknown in humans. M/P ratio not available. Potential for serious adverse reactions in nursing infants.
No specific dose adjustments are recommended based on pharmacokinetic changes in pregnancy. Use the minimum amount necessary to control symptoms, and avoid application to large body surface areas or prolonged use. Systemic absorption is minimal and unlikely to be altered significantly during pregnancy.
No dose adjustment necessary; use minimal amount to control symptoms. Systemic absorption is negligible, so pharmacokinetic changes in pregnancy do not alter dosing.
Pimecrolimus is a topical calcineurin inhibitor used for mild-to-moderate atopic dermatitis. It is not indicated for use in children under 2 years. Avoid use on infected skin; monitor for local irritation. Long-term safety concerns include potential increased risk of lymphoma and skin malignancies; use minimal amounts for shortest duration necessary. Do not use with occlusive dressings. Consider intermittent therapy for flares.
Topical calcineurin inhibitor for atopic dermatitis, reserved as second-line therapy for mild-to-moderate eczema due to boxed warning for rare malignancy risk. Apply thin layer only; avoid occlusive dressings. Do not use in immunocompromised patients. Intermittent use is recommended; continuous long-term use safety not established.
Apply a thin layer only to affected areas, avoiding eyes, mouth, and broken skin.,Do not cover treated area with bandages or wraps unless directed by your doctor.,Wash hands after applying unless treating hands.,Avoid sun exposure, tanning beds, and UV therapy while using this medication.,Report any signs of infection, skin burning, or worsening rash.,Do not use for prolonged periods; use only until symptoms clear.,Inform your doctor if you are pregnant, breastfeeding, or have a weakened immune system.
Apply only to affected skin areas; avoid eyes, mouth, and open wounds.,Use for short durations; do not use continuously for extended periods.,Avoid sun exposure and tanning beds; use sunscreen on treated areas.,Do not cover treated skin with bandages or wraps unless instructed.,Report any signs of infection, skin burning, or new skin growths to your doctor.,This drug is for external use only; wash hands after application unless treating hands.,Do not use if you have a weakened immune system or active skin infection.
"Pimecrolimus, a calcineurin inhibitor, and panobinostat, a histone deacetylase inhibitor, both have immunosuppressive and potential myelosuppressive effects. Concurrent use may synergistically increase the risk of infections, including opportunistic infections, and hematologic toxicities such as neutropenia, thrombocytopenia, and anemia. Additionally, both drugs can prolong the QT interval, potentially increasing the risk of serious cardiac arrhythmias like torsade de pointes."
"Pimecrolimus, a calcineurin inhibitor used topically, can inhibit CYP3A4 activity to a mild degree, potentially decreasing the metabolism of nilotinib, a BCR-ABL tyrosine kinase inhibitor that is predominantly metabolized by CYP3A4. This may lead to increased nilotinib plasma concentrations, elevating the risk of QT interval prolongation, hepatotoxicity, and other dose-related adverse effects. Therefore, patients should be carefully monitored for signs of nilotinib toxicity."
"Pimecrolimus and sirolimus both suppress immune function via distinct but overlapping mechanisms. Pimecrolimus inhibits calcineurin, reducing T-cell activation, while sirolimus inhibits mTOR, blocking cytokine-driven T-cell proliferation. Concomitant use increases the risk of over-immunosuppression, leading to higher susceptibility to infections, lymphoproliferative disorders, and possibly nephrotoxicity."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PIMECROLIMUS vs ELIDEL, answered by our medical review team.
PIMECROLIMUS is a Calcineurin Inhibitor that works by Pimecrolimus is a calcineurin inhibitor that binds to macrophilin-12 (FKBP-12) and inhibits calcineurin-dependent T-cell activation, thereby suppressing pro-inflammatory cytokine production (e.g., IL-2, IFN-γ) and mast cell degranulation.. ELIDEL is a Topical Calcineurin Inhibitor that works by Inhibits T-cell activation by binding to macrophilin-12 (FKBP-12) and inhibiting calcineurin, thereby blocking cytokine transcription.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PIMECROLIMUS and ELIDEL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PIMECROLIMUS is: Topical: Apply a thin layer of 1% cream to affected areas twice daily. Maximum daily dose: not established; usual amount is pea-sized per application. Not for continuous long-term use; intermittent use only.. The standard adult dose of ELIDEL is: Apply a thin layer of 1% cream to affected areas twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PIMECROLIMUS and ELIDEL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PIMECROLIMUS is classified as Category A/B. Pimecrolimus is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and fetotoxicity at doses 35 times the maximum recommended human dose. There are no. ELIDEL is classified as Category C. FDA Pregnancy Category C. Systemic exposure is minimal after topical application, but animal studies have shown developmental toxicity. No adequate human studies; risk cannot be ex. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.